The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer.
Norio Kohno
No relevant relationships to disclose
Yoshie Hasegawa
No relevant relationships to disclose
Jun Horiguchi
No relevant relationships to disclose
Takashi Ishikawa
No relevant relationships to disclose
Daishu Miura
No relevant relationships to disclose
Mitsuhiro Hayashi
No relevant relationships to disclose
Shintaro Takao
No relevant relationships to disclose
Seung Jin Kim
No relevant relationships to disclose
Hirokazu Tanino
No relevant relationships to disclose
Kohei Akazawa
No relevant relationships to disclose